Mucosal Viral Vector Formulations for Room-Temperature Vaccine Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing injectable vaccines face challenges such as iatrogenic pain, safety risks for medical staff and patients, instability at ambient temperatures, and require refrigeration, limiting their widespread use and accessibility.
Innovation Solution
Development of immunogenic compositions using recombinant virus vectors formulated with PMAL-C16 or zwitterionic surfactants, which can be administered via mucosal routes and maintain stability at room temperature, including formulations in liquid or solid carriers with pH buffering agents and stabilizing agents like sugars and polymers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If injectable vaccines are used, then immune protection is achieved, but iatrogenic pain and safety risks increase
Solution Approach 1:
The patent replaces the mechanical injection system with a mucosal delivery system. The vaccine composition is administered orally or via other non-injectable routes, eliminating needles and associated pain/safety risks while maintaining immune protection through mucosal absorption and immune stimulation
2Ease of manufacture
If most vaccines are formulated without special stabilizers, then manufacturing is simpler, but they become unstable at ambient temperatures and require refrigeration
Solution Approach 1:
The patent formulates a composite vaccine composition containing the antigen combined with specific stabilizing agents and excipients. This composite formulation provides ambient temperature stability while maintaining manufacturability, as the stabilizers protect the antigen during storage and handling without requiring complex manufacturing processes
Solution Approach 2:
The patent modifies the physical and chemical parameters of the vaccine formulation by incorporating stabilizers, buffers, and protective agents. These parameter changes enable the vaccine to maintain stability across a broader temperature range, eliminating the need for strict refrigeration while preserving antigen efficacy
3Stability of the object's composition
If refrigeration is required for vaccine storage, then vaccine stability is maintained, but accessibility and widespread use are limited
Solution Approach 1:
The patent extracts the refrigeration requirement from the vaccine storage system by incorporating ambient-stable formulations. The vaccine is designed to remain stable at room temperature through the use of stabilizing agents and optimized formulation, removing the dependency on cold chain infrastructure and thereby improving accessibility in remote and resource-limited settings
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide stable and effective immune responses with reduced pain and safety risks, enabling administration without refrigeration and improving accessibility.
Implementation Method 1
recombinant virus vector formulated in a pharmaceutically acceptable carrier comprising: (i) PMAL-C16 or (ii) from about 0.1% to 10% of a zwitterionic surfactant
Implementation Method 2
the carrier also comprises a pH buffering agent (e.g., phosphate buffered saline). In certain aspects, the carrier has a pH of between 5.0 and 8.0
Data Source
AI summary
Immunogenic compositions comprising viral vectors and surfactants are provided. Methods for administration and preparation of such compositions are also provided.